Methods for improving the immunogenicity and efficacy of cancer vaccines

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

(2018) S Aspeslagh et al.   ANNALS OF ONCOLOGY

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria

(2017) Leena Gandhi et al.   EUROPEAN JOURNAL OF CANCER

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

(2017) Cristina Maccalli et al.   IMMUNOLOGICAL INVESTIGATIONS

CSPG4: a prototype oncoantigen for translational immunotherapy studies

(2017) Valeria Rolih et al.   Journal of Translational Medicine

Epigenetics in cancer stem cells

(2017) Tan Boon Toh et al.   Molecular Cancer

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

A STING-activating nanovaccine for cancer immunotherapy

(2017) Min Luo et al.   Nature Nanotechnology

Chromatin dependencies in cancer and inflammation

(2017) Ivan Marazzi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy

(2017) Mirjana Efremova et al.   Frontiers in Immunology

Novel Pancreatic Cancer Vaccines Could Unleash the Army Within

(2017) Gregory M. Springett   Cancer Control

Intrinsic immunogenicity of rapidly-degradable polymers evolves during degradation

(2016) James I. Andorko et al.   Acta Biomaterialia

Determination of the Absolute Number Concentration of Nanoparticles and the Active Affinity Sites on Their Surfaces

(2016) Cong-Ying Wen et al.   ANALYTICAL CHEMISTRY

Combining Epigenetic and Immunotherapy to Combat Cancer

(2016) Katherine B. Chiappinelli et al.   CANCER RESEARCH

Recent innovations in mRNA vaccines

(2016) Jeffrey B Ulmer et al.   CURRENT OPINION IN IMMUNOLOGY

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

(2016) Jon Bjoern et al.   CYTOTHERAPY

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma

(2016) Stephan Grabbe et al.   Nanomedicine

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Designer vaccine nanodiscs for personalized cancer immunotherapy

(2016) Rui Kuai et al.   NATURE MATERIALS

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

(2016) Qian Chen et al.   Nature Communications

Improving the clinical impact of biomaterials in cancer immunotherapy

(2016) Joshua M. Gammon et al.   Oncotarget

HSP70-based anti-cancer immunotherapy

(2016) Irina V. Guzhova et al.   Human Vaccines & Immunotherapeutics

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

(2016) Steve Boudewijns et al.   OncoImmunology

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer

(2015) T. Donnem et al.   ANNALS OF ONCOLOGY

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

(2015) Gaetano Finocchiaro et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes

(2015) Daniele Mennonna et al.   GUT

Immunotherapy for breast cancer: is it feasible?

(2015) Leisha A Emens et al.   Immunotherapy

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Shape and size-dependent immune response to antigen-carrying nanoparticles

(2015) Sunny Kumar et al.   JOURNAL OF CONTROLLED RELEASE

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

Heat shock protein vaccines against glioblastoma: from bench to bedside

(2015) Leonel Ampie et al.   JOURNAL OF NEURO-ONCOLOGY

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

(2015) Cornelia L Trimble et al.   LANCET

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

Injectable cryogel-based whole-cell cancer vaccines

(2015) Sidi A. Bencherif et al.   Nature Communications

RNA-Based Vaccines in Cancer Immunotherapy

(2015) Megan A. McNamara et al.   Journal of Immunology Research

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark

(2015) Guido Kroemer et al.   OncoImmunology

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

(2015) Jonathan Pol et al.   OncoImmunology

T-cell therapy against cancer mutations

(2015) Eric Tran et al.   Oncotarget

Surface chemistry dependent immunostimulative potential of porous silicon nanoplatforms

(2014) Mohammad-Ali Shahbazi et al.   BIOMATERIALS

Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

(2014) Zlatko Trajanoski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer stem cells: perspectives for therapeutic targeting

(2014) Cristina Maccalli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis

(2014) Matilde Todaro et al.   Cell Stem Cell

Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells

(2014) Aaron P. Rapoport et al.   CLINICAL CANCER RESEARCH

A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma

(2014) Jianping Yuan et al.   Journal of Hematology & Oncology

Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients

(2014) Lisa H Butterfield et al.   Journal of Translational Medicine

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

(2014) Osama E Rahma et al.   Journal of Translational Medicine

Structure-based programming of lymph-node targeting in molecular vaccines

(2014) Haipeng Liu et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Biopolymer implants enhance the efficacy of adoptive T-cell therapy

(2014) Sirkka B Stephan et al.   NATURE BIOTECHNOLOGY

Therapeutic vaccines for cancer: an overview of clinical trials

(2014) Ignacio Melero et al.   Nature Reviews Clinical Oncology

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomaterials for Nanoparticle Vaccine Delivery Systems

(2014) Preety Sahdev et al.   PHARMACEUTICAL RESEARCH

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

Erasers of Histone Acetylation: The Histone Deacetylase Enzymes

(2014) E. Seto et al.   Cold Spring Harbor Perspectives in Biology

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

(2014) A. Young et al.   Cancer Discovery

Peptide-based vaccines for cancer therapy

(2014) Giorgio Parmiani et al.   Human Vaccines & Immunotherapeutics

The immune landscape of human tumors

(2014) Gabriela Bindea et al.   OncoImmunology

A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma

(2014) Giorgio Parmiani et al.   OncoImmunology

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells

(2013) Joel C. Sunshine et al.   BIOMATERIALS

Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma

(2013) Einar Osland Vik-Mo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

(2013) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Epigenetic modulation of the immune function

(2013) Beatriz Suárez-Álvarez et al.   Epigenetics

Dendritic-Cell-Based Therapeutic Cancer Vaccines

(2013) Karolina Palucka et al.   IMMUNITY

The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response

(2013) Emily F. Stamell et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Uptake of Nanoparticles and Microparticles by Pulmonary APC Subsets Induces Discrete Immunological Imprints

(2013) C. L. Hardy et al.   JOURNAL OF IMMUNOLOGY

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

(2013) Charles Butts et al.   LANCET ONCOLOGY

The regulatory landscape for actively personalized cancer immunotherapies

(2013) Cedrik M Britten et al.   NATURE BIOTECHNOLOGY

Immunotherapy at Large: The road to personalized cancer vaccines

(2013) Robert H Vonderheide et al.   NATURE MEDICINE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

(2013) Orin Bloch et al.   NEURO-ONCOLOGY

The Yin and Yang of Toll-like receptors in cancer

(2013) J-P Pradere et al.   ONCOGENE

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

(2013) Daniel M Geynisman et al.   Journal for ImmunoTherapy of Cancer

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

(2012) S. J. Dovedi et al.   BLOOD

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

(2012) Kelly Barrios et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity

(2012) N. Ning et al.   CANCER RESEARCH

HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers

(2012) Marc L. Mendillo et al.   CELL

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides

(2012) P. Filipazzi et al.   CLINICAL CANCER RESEARCH

Improving T cell responses to modified peptides in tumor vaccines

(2012) Jonathan D. Buhrman et al.   IMMUNOLOGIC RESEARCH

The future of human DNA vaccines

(2012) Lei Li et al.   JOURNAL OF BIOTECHNOLOGY

HLA Anchor Optimization of the Melan-A-HLA-A2 Epitope within a Long Peptide Is Required for Efficient Cross-Priming of Human Tumor-Reactive T Cells

(2012) J.-M. Chauvin et al.   JOURNAL OF IMMUNOLOGY

Nanoparticle Hydrophobicity Dictates Immune Response

(2012) Daniel F. Moyano et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects

(2012) Alison C. West et al.   OncoImmunology

Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements

(2012) Maha Z. Ladjemi   Frontiers in Oncology

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

(2011) Y. H. Kim et al.   BLOOD

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

(2011) Jianda Yuan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy

(2011) Teofila Seremet et al.   CANCER JOURNAL

Autologous Versus Allogeneic Cell-Based Vaccines?

(2011) Giorgio Parmiani et al.   CANCER JOURNAL

Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma

(2011) Masanobu Kano et al.   CANCER SCIENCE

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012

(2011) L Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Cytoplasmic DNA innate immune pathways

(2011) Glen N. Barber   IMMUNOLOGICAL REVIEWS

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

(2011) A. J. Christiansen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interconversion Between Intestinal Stem Cell Populations in Distinct Niches

(2011) N. Takeda et al.   SCIENCE

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

(2011) Dmitri Smirnov et al.   VACCINE

Peptide Vaccination after T-Cell Transfer Causes Massive Clonal Expansion, Tumor Eradication, and Manageable Cytokine Storm

(2010) L. V. Ly et al.   CANCER RESEARCH

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines

(2010) Luis E. Fernandez et al.   Clinical & Developmental Immunology

Combining low-dose cyclophosphamide with GM-CSF–secreting prostate cancer immunotherapy enhances antitumor immune effects

(2010) Emmanuel S Antonarakis et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

(2010) Lorna Rettig et al.   INTERNATIONAL JOURNAL OF CANCER

Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant

(2010) Bo Jin et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy

(2010) Emilie Fauquembergue et al.   JOURNAL OF IMMUNOTHERAPY

DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer

(2010) Jordan T. Becker et al.   JOURNAL OF IMMUNOTHERAPY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy

(2009) J. Kohlmeyer et al.   CANCER RESEARCH

Recent development in carbohydrate-based cancer vaccines

(2009) Zhongwu Guo et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Multipeptide vaccination in cancer patients

(2009) Lorenzo Pilla et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer

(2009) Douglas G. McNeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

(2009) Lisa H. Butterfield et al.   JOURNAL OF IMMUNOTHERAPY

Infection-mimicking materials to program dendritic cells in situ

(2009) Omar A. Ali et al.   NATURE MATERIALS

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature

(2008) P. C. Maciag et al.   CANCER RESEARCH

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire

(2008) Jason Rice et al.   EUROPEAN JOURNAL OF IMMUNOLOGY